US2016257735A1PendingUtilityA1

Regulation of npvf gene and its products: a method for modulating energy imbalance

11
Individually held — no corporate assignee on recordPriority: Mar 2, 2015Filed: Oct 8, 2015Published: Sep 8, 2016
Est. expiryMar 2, 2035(~8.6 yrs left)· nominal 20-yr term from priority
Inventors:Leslie P. KozakJulia Jaroslawska
C12N 2310/14A61K 31/713C12N 15/113A61K 31/165A61K 31/4045A01K 2227/105A01K 2267/0362C12N 15/1136A61K 38/1709A01K 67/0276A61K 45/06C12Q 1/6883C12Q 2600/158A61K 31/7105A61P 3/04A61K 31/16C07K 16/18C07K 2317/76
11
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to methods for modulating energy utilization by targeting the Npvf pathway. Inhibition of the Npvf pathway promotes energy utilization in a subject.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for promoting energy utilization in a subject, comprising
 administering to the subject an effective amount of a Npvf pathway inhibitor to promote energy utilization.   
     
     
         2 . The method of  claim 1 , wherein the Npvf pathway inhibitor is an Npvf pathway antagonist. 
     
     
         3 . The method of  claim 2 , wherein the Npvf pathway antagonist is an anti-RFRP3 antibody or an anti-RFRP1 antibody. 
     
     
         4 . The method of  claim 2 , wherein the Npvf pathway antagonist is RF9 or BIBP3226. 
     
     
         5 . The method of  claim 1 , wherein the Npvf pathway inhibitor is an expression inhibitor. 
     
     
         6 . The method of  claim 5 , wherein the expression inhibitor is an inhibitory nucleic acid. 
     
     
         7 . The method of  claim 6 , wherein the inhibitory nucleic acid is an antisense oligonucleotide. 
     
     
         8 . The method of  claim 6 , wherein the inhibitory nucleic acid is a siRNA. 
     
     
         9 . The method of  claim 1 , wherein the Npvf pathway inhibitor is administered orally. 
     
     
         10 . The method of  claim 1 , wherein the Npvf pathway inhibitor is administered by injection. 
     
     
         11 . The method of  claim 1  further comprising administering to the subject a dopamine antagonist. 
     
     
         12 . A method for treating a wasting disorder in a subject, comprising
 administering to the subject an effective amount of a Npvf pathway inducing agent to reduce energy utilization.   
     
     
         13 . The method of  claim 12 , wherein the wasting disorder is anorexia nervosa. 
     
     
         14 . The method of  claim 12 , wherein the Npvf pathway inducing agent is exogenous Npvf. 
     
     
         15 . The method of  claim 14 , wherein the exogenous Npvf comprises RFRP1. 
     
     
         16 . The method of  claim 14 , wherein the exogenous Npvf comprises RFRP3. 
     
     
         17 . The method of  claim 14 , wherein the exogenous Npvf comprises RFRP1 and RFPR3. 
     
     
         18 . The method of  claim 12 , wherein the Npvf pathway inducing agent is an Npvf expression vector. 
     
     
         19 . The method of  claim 12 , wherein the Npvf pathway inducing agent is an Npvf mRNA. 
     
     
         20 . The method of  claim 12 , wherein the Npvf pathway inducing agent is an Npvf activator selected that is melatonin. 
     
     
         21 . The method of  claim 12 , wherein the Npvf pathway inducing agent is an NPFF-R1 agonist. 
     
     
         22 . The method of  claim 12 , wherein the Npvf pathway inducing agent is an NPFF-R2 agonist. 
     
     
         23 . The method of  claim 12 , further comprising administering to the subject a dopaminergic pathway antagonist. 
     
     
         24 . The method of  claim 12 , wherein the Npvf pathway inducing agent is administered orally. 
     
     
         25 . The method of  claim 12 , wherein the Npvf pathway inducing agent is administered by injection.

Join the waitlist — get patent alerts

Track US2016257735A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.